Global Pyrogen Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Pyrogen Testing Market Segmentation, By Product (Kits and Reagents, Services and Instruments), Application (Pharmaceutical and Biotech Companies, Food and Beverages Companies, Medical Device Manufacturing, Biomedical companies and Others), Test Type (LAL Tests, TAL Test, MAT Test, Recombinant Factor C Assay, In Vitro Tests and Rabbit Pyrogen Tests) – Industry Trends and Forecast to 2032

Pyrogen Testing Market Size

• The global pyrogen testing market size was valued at USD 1.50 billion in 2024 and is expected to reach USD 3.99 billion by 2032, at a CAGR of 13.00% during the forecast period
• This growth is driven by factors such as the rising incidence of infectious disease, growing biopharmaceutical and biotechnology industry

Pyrogen Testing Market Analysis

• Pyrogen Testing is a critical quality control process in the pharmaceutical and biotechnology industries, used to detect and quantify pyrogens (fever-inducing substances) in drugs, biologics, and medical devices. It ensures patient safety by preventing harmful immune responses triggered by contaminated products
• The demand for pyrogen testing is significantly driven by the stringent regulatory requirements for drug safety, the growing biopharmaceutical industry, and increasing focus on patient safety. The need for accurate and reliable testing methods, such as the Limulus Amebocyte Lysate (LAL) test, recombinant factor C (rFC) assay, and monocyte activation test (MAT), further supports market growth
• North America is expected to dominate the pyrogen testing market with 45.9% market share, driven by a robust healthcare infrastructure, strict regulatory requirements, and high demand for pyrogen testing in pharmaceutical and medical device manufacturing
• Asia-Pacific is expected to be the fastest growing region in the pyrogen testing market, with 35.5% market share, driven by rapid industrialization, increasing healthcare expenditure, and growing awareness about the importance of endotoxin testing
• Kits and reagents segment is expected to dominate the market with a market share of 63.4%. This dominance is attributed to the increasing demand for high-quality reagents and kits essential for pyrogen detection in pharmaceuticals, biologics, and medical devices. The growing focus on ensuring product safety and compliance with stringent regulatory standards further drives the demand for these consumables

Report Scope and Pyrogen Testing Market Segmentation

Pyrogen Testing Market Trends

“Advancements in Pyrogen Testing Technologies”

• One significant trend in the pyrogen testing market is the growing adoption of advanced, non-animal-based testing methods, driven by the demand for faster, more accurate, and ethically sound alternatives to traditional animal-based tests
• These innovations include recombinant Factor C (rFC) assays, Monocyte Activation Tests (MAT), and in vitro assays, which offer reliable and reproducible results while reducing the need for animal testing 

  • For instance, rFC assays have gained significant traction due to their high sensitivity, shorter testing times, and compliance with global regulatory guidelines, making them an ideal choice for modern biopharmaceutical and medical device testing

• These advancements are transforming the pyrogen testing landscape, improving product safety, reducing costs, and supporting the industry's shift towards more sustainable and humane testing practices

Driver

“Rising Demand for Biologics and Vaccines”

• The increasing demand for biologics, vaccines, and injectable drugs is a major driver for the pyrogen testing market, as these products must undergo rigorous safety testing to prevent harmful pyrogenic reactions in patients
• With the global biopharmaceutical market expanding rapidly, the need for effective pyrogen detection methods has grown, ensuring the safety and quality of these critical therapeutics
• In addition, the COVID-19 pandemic has significantly boosted the demand for vaccines and biologics, further driving the need for accurate pyrogen testing solutions

For instance,

• In March 2023, according to a report by the World Health Organization (WHO), global vaccine production capacity has increased substantially, with an estimated 20 billion vaccine doses being produced annually, highlighting the critical need for effective pyrogen testing to ensure patient safety 
• As a result, the growing demand for biologics and vaccines is expected to significantly drive the pyrogen testing market, supporting the expansion of the biopharmaceutical industry

Opportunity

“Shifting Focus Towards Non-Animal Testing Methods”

• The increasing emphasis on ethical testing and the global push to reduce animal-based testing have created significant opportunities for alternative pyrogen testing methods, such as the Monocyte Activation Test (MAT) and recombinant Factor C (rFC) assays
• These innovative methods offer comparable accuracy to traditional rabbit pyrogen tests while aligning with regulatory requirements and ethical standards

For instance,

• In April 2024, the European Medicines Agency (EMA) announced support for the transition to non-animal-based pyrogen testing methods, encouraging biopharmaceutical companies to adopt these technologies as part of their quality control processes 
• The move towards more ethical and sustainable testing approaches is expected to drive the adoption of these advanced pyrogen testing methods, creating significant growth opportunities for the market

Restraint/Challenge

“High Costs of Advanced Testing Methods”

• The high cost of implementing advanced pyrogen testing methods, such as rFC assays and MAT, poses a significant challenge for small to medium-sized biopharmaceutical companies
• These methods, while offering superior accuracy and ethical advantages, often require specialized equipment, skilled personnel, and significant upfront investments, limiting their adoption in cost-sensitive markets
• In addition, the stringent regulatory requirements for validating and adopting these alternative methods can further delay their widespread acceptance

For instance,

• In June 2024, according to a report by the Biotechnology Innovation Organization (BIO), smaller biotech companies have expressed concerns over the high costs and complex validation processes associated with transitioning to non-animal-based pyrogen testing methods, highlighting a key barrier to market growth 
• As a result, the high costs and regulatory hurdles associated with advanced pyrogen testing methods continue to pose significant challenges, potentially slowing the market's overall expansion

Pyrogen Testing Market Dynamics

In 2025, the kits and reagents Stimulation is projected to dominate the market with a largest share in products segment

The kits and reagents segment is expected to dominate the pyrogen testing market with the largest share of 63.4% in 2025. This dominance is attributed to the increasing demand for high-quality reagents and kits essential for pyrogen detection in pharmaceuticals, biologics, and medical devices. The growing focus on ensuring product safety and compliance with stringent regulatory standards further drives the demand for these consumables.

The LAL test is expected to account for the largest share during the forecast period in test type market

In 2025, the LAL test segment is expected to dominate the market with the largest market share of 60.8% due to its high sensitivity, cost-effectiveness, and reliability in detecting endotoxins. As the preferred method in pharmaceutical and medical device manufacturing, the LAL test provides rapid results and aligns with stringent regulatory requirements, making it a critical component in ensuring product safety and compliance.

Pyrogen Testing Market Regional Analysis

“North America is Expected to Dominate the Pyrogen Testing Market”

• North America is expected to account for approximately 45.9% of the global pyrogen testing market share, driven by a robust healthcare infrastructure, strict regulatory requirements, and high demand for pyrogen testing in pharmaceutical and medical device manufacturing
• U.S. is projected to hold 42.4% of the global market share due to its established pharmaceutical industry, ongoing research activities, and adherence to the U.S. Food and Drug Administration (FDA) regulations regarding endotoxin testing
• In addition, significant investments in biotechnology, medical devices, and pharmaceuticals, along with the growing focus on safety and regulatory compliance, continue to bolster market growth in the region

“Asia-Pacific to Register the Highest Growth Rate in the Pyrogen Testing Market”

• Asia-Pacific is anticipated to register the highest CAGR in the pyrogen testing market, accounting for 35.5% of the global market share, driven by rapid industrialization, increasing healthcare expenditure, and growing awareness about the importance of endotoxin testing
• Countries such as China, India, and Japan are emerging as key markets due to their expanding pharmaceutical and biotechnology industries, large patient populations, and a rising need for compliance with global safety standards in drug and medical device manufacturing
• India, in particular, is expected to witness the highest growth rate with a CAGR of 12.9%, due to increased government investment in healthcare infrastructure, a growing biotechnology sector, and rising demand for high-quality pharmaceutical products

Pyrogen Testing Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Charles River Laboratories (U.S.)
• Lonza (Switzerland)
• Merck KGaA (Germany)
• Ellab A/S (Denmark)
• GenScript (U.S.) 
• Thermo Fisher Scientific Inc. (U.S.)
• WuXi AppTec (China)
• ASSOCIATES OF CAPE COD, INC. (U.S.)
• Sanquin (Netherlands)
• Minerva Analytix GmbH (Germany)
• InvivoGen (U.S.)
• Microcoat Biotechnologie GmbH (Germany)
• North American Science Associates, LLC (U.S.)
• Creative Bioarray (U.S.)
• INDOOR Biotechnologies, Inc. (U.S.)

Latest Developments in Global Pyrogen Testing Market

• In October 2023, Lonza introduced the PyroCell MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, enhancing and streamlining pyrogen testing without the use of rabbits
• In June 2024, the European Pharmacopoeia Commission announced the removal of the Rabbit Pyrogen Test (RPT) from its monographs, replacing it with in vitro alternatives such as the Monocyte Activation Test (MAT). This change will take effect on July 1, 2025.
• In August 2023, Lonza launched the Nebula Absorbance Reader, a new absorbance microplate reader, expanding its range of optimized instruments for efficient endotoxin and pyrogen testing

SKU-14353